Hepion Pharmaceuticals Inc

NASDAQ HEPA

Data sourced from iex and EODHD
Download Data

Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio 2 year CAGR for the year ending December 31, 2023: -53.95%

Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio 2 year CAGR is -53.95% for the year ending December 31, 2023, a -314.83% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2022 was 6.16, a -43.32% change year over year.
  • Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2021 was 10.88, a 33.51% change year over year.
  • Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2020 was 8.15, a -22.38% change year over year.
  • Hepion Pharmaceuticals Inc Working Capital to Current Liabilities Ratio for the year ending December 31, 2019 was 10.49, a 25,206.61% change year over year.
NASDAQ: HEPA

Hepion Pharmaceuticals Inc

CEO Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
IPO Date Feb. 11, 2014
Location United States
Headquarters 399 Thornall Street, Edison, NJ, United States, 08837
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Similar companies

AVRO

AVROBIO Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email